Intensity Therapeutics Issued New Patents for Technology Platform

Download as PDF
  • US Patent 9,636,406 broadens existing claims for the Company’s proprietary technology
  • Australia intends to grant the Company patent 2013318338

WESTPORT, Conn.--(BUSINESS WIRE)-- Intensity Therapeutics, Inc., a privately held clinical-stage, biotechnology company developing proprietary cancer immunotherapy products, today announced that the United States Patent and Trademark Office (PTO) issued the Company patent 9,636,406. In addition, the Company noted that the Australian PTO intends to grant Intensity patent 2013318338.

“Intensity’s DfuseRxSM platform has identified our lead drug, INT230-6. This novel product, now in clinical trials, has shown great promise in regressing tumors and extending life in animal models of metastatic cancer,” said Intensity’s President and CEO, Lewis H. Bender. “The newly issued U.S. patent and soon-to-be issued Australian patent allow us to protect our unique technology. The Company now has multiple issued patents and several patent applications in the U.S. and countries around the world. U.S. patent 9,636,406 and near-term issuance of Australian patent 2013318338 increases the likelihood that our products can be secured in important markets.”

About INT230-6

INT230-6 is a novel, anti-cancer drug for direct intratumoral injection. The product contains potent anti-cancer agents that disperse throughout tumors and diffuse into cancer cells. INT230-6 was identified from Intensity’s DfuseRxSM platform. In preclinical studies INT230-6 eradicated tumors by a combination of direct tumor kill coupled with recruitment of dendritic cells to the tumor micro-environment that stimulated anti-cancer T-cell activation. INT230-6 provides complete responder animals with long-term, durable protection from multiple re-inoculations of the initial cancer and resistance to other cancers. INT230-6 is being evaluated in clinical study, IT-01. Further information on the human trial can be found at www.clinicaltrials.gov (NCT#03058289).

About Intensity Therapeutics, Inc.

Intensity Therapeutics, Inc. is a clinical-stage biotechnology company whose mission is to greatly extend the lives of patients with cancer. Intensity Therapeutics is pioneering a new immune-based approach to treat cancer. The Company uses its DfuseRxSM platform technology to create new drug formulations that disperse throughout a tumor and diffuse into cancer cells. Drug products created using the technology are capable of attenuating (killing) a tumor in a manner that allows for the adaptive immune system to recognize the cancer and attack distal tumors and micrometastases. Further information can be found at www.intensitytherapeutics.com.

Forward-Looking Statements

This press release contains forward-looking statements regarding Intensity Therapeutics’ plans, future operations and objectives. Such statements involve known and unknown risks, uncertainties and other factors that may cause actual performance or achievements to be materially different from those currently anticipated. These forward-looking statements include, among other things, statements about the initiation and timing of future clinical trials.

Investors:
Intensity Therapeutics, Inc.
Lewis Bender
President & CEO
61 Wilton Road, 3rd Floor
Westport, CT 06880
203-221-7377
lbender@intensitytherapeutics.com
or
Media:
Scienta Communications
Aline Sherwood
312-238-8957
asherwood@scientapr.com

Source: Intensity Therapeutics, Inc.

Released June 15, 2017